Phyxiom

Executive Summary

Phyxiom is a digital health company based in Dublin, Ireland, dedicated to improving clinical outcomes for patients with uncontrolled asthma and COPD. Founded in 2018, the company leverages over 12 years of clinical research and multiple randomized controlled trials to develop patented algorithms and software platforms for chronic respiratory disease management. With a mission to serve the 540 million patients globally affected by these conditions, Phyxiom's technology aims to enhance disease monitoring, treatment adherence, and remote patient management. The company's solutions are positioned to address significant unmet needs in respiratory care, potentially reducing hospitalizations and improving quality of life. As a private entity with no disclosed funding or valuation, Phyxiom likely operates in early commercialization or late-development stages, focusing on regulatory clearance and market entry.

Upcoming Catalysts (preview)

• Q3 2026Regulatory submission for CE marking or FDA clearance of asthma management platform60% success
• Q4 2026Publication of positive results from ongoing real-world study in COPD70% success
• Q1 2027Strategic partnership with a pharmaceutical company for digital therapeutic integration40% success